STOCK TITAN
  1. Home
  2. Sec-filings
  3. CNTA
  4. [Form 4] Centessa Pharmaceuticals plc Insider Trading Activity

CNTA Form 4: 8,000-share sale at $25; 5,000 exercised at $8.01

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Centessa Pharmaceuticals (CNTA) reported an insider transaction by its President, Orexin Program. On 10/27/2025, the officer exercised 5,000 options at $8.01 and sold 8,000 ordinary shares at $25. Following these transactions, the reporting person beneficially owned 194,394 shares (direct). The sales were effected under a Rule 10b5-1 trading plan adopted on February 14, 2025. The filer also reported 30,000 derivative securities (options) remaining. Each ADS currently represents one ordinary share.

Positive

  • None.

Negative

  • None.
Insider Accardi Mario Alberto
Role President, Orexin Program
Sold 8,000 shs ($200K)
Type Security Shares Price Value
Exercise Share Option (right to buy) 5,000 $0.00 --
Exercise Ordinary Shares 5,000 $8.01 $40K
Sale Ordinary Shares 8,000 $25.00 $200K
Holdings After Transaction: Share Option (right to buy) — 30,000 shares (Direct); Ordinary Shares — 202,394 shares (Direct)
Footnotes (1)
  1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 14, 2025. 1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2024.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
 Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Accardi Mario Alberto
(Last) (First) (Middle)
C/O CENTESSA PHARMACEUTICALS PLC
3RD FL., 1 ASHLEY RD, ALTRINCHAM
(Street)
CHESHIRE X0 WA14 2DT
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Centessa Pharmaceuticals plc [ CNTA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President, Orexin Program
3. Date of Earliest Transaction (Month/Day/Year)
10/27/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares(1) 10/27/2025 M 5,000 A $8.01 202,394 D
Ordinary Shares(1) 10/27/2025 S(2) 8,000 D $25 194,394 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Share Option (right to buy) $8.01 10/27/2025 M 5,000 (3) 02/01/2034 Ordinary Shares(1) 5,000 $0 30,000 D
Explanation of Responses:
1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
2. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on February 14, 2025.
3. 1/48th of the shares subject to such option shall vest and become exercisable in equal monthly installments with the first installment vesting on March 1, 2024.
Remarks:
/s/ Raphael Deferiere, attorney-in-fact 10/27/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did CNTA disclose on this Form 4?

An officer exercised 5,000 options at $8.01 and sold 8,000 shares at $25 on 10/27/2025.

Who is the reporting person and their role at CNTA?

The reporting person is an Officer, serving as President, Orexin Program.

How many CNTA shares are owned after the transactions?

The reporting person beneficially owned 194,394 shares (direct) after the reported transactions.

Were the CNTA share sales under a Rule 10b5-1 plan?

Yes. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on February 14, 2025.

What options remain after the CNTA transactions?

The filer reported 30,000 derivative securities (options) beneficially owned following the transactions.

What was the sale price for the CNTA shares?

The 8,000 shares were sold at $25 per share.

How are CNTA ordinary shares represented in ADS form?

Each American Depositary Share currently represents one ordinary share.